Log in

NASDAQ:EARS - Auris Medical Stock Price, Forecast & News

-0.04 (-2.82 %)
(As of 12/6/2019 04:00 PM ET)
Today's Range
Now: $1.38
50-Day Range
MA: $1.58
52-Week Range
Now: $1.38
Volume130,380 shs
Average Volume149,832 shs
Market Capitalization$2.59 million
P/E RatioN/A
Dividend YieldN/A
Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:EARS



Sales & Book Value

Annual SalesN/A
Book Value$1.99 per share



Market Cap$2.59 million
Next Earnings Date12/12/2019 (Estimated)
OptionableNot Optionable

Receive EARS News and Ratings via Email

Sign-up to receive the latest news and ratings for EARS and its competitors with MarketBeat's FREE daily newsletter.

Auris Medical (NASDAQ:EARS) Frequently Asked Questions

What is Auris Medical's stock symbol?

Auris Medical trades on the NASDAQ under the ticker symbol "EARS."

When did Auris Medical's stock split? How did Auris Medical's stock split work?

Auris Medical shares reverse split on the morning of Wednesday, May 1st 2019. The 1-20 reverse split was announced on Tuesday, April 30th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 30th 2019. An investor that had 100 shares of Auris Medical stock prior to the reverse split would have 5 shares after the split.

How were Auris Medical's earnings last quarter?

Auris Medical Holding Ltd (NASDAQ:EARS) posted its earnings results on Thursday, May, 11th. The biotechnology company reported ($4.40) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($2.80) by $1.60. View Auris Medical's Earnings History.

When is Auris Medical's next earnings date?

Auris Medical is scheduled to release their next quarterly earnings announcement on Thursday, December 12th 2019. View Earnings Estimates for Auris Medical.

What price target have analysts set for EARS?

1 brokers have issued 1-year target prices for Auris Medical's stock. Their forecasts range from $100.00 to $100.00. On average, they expect Auris Medical's stock price to reach $100.00 in the next year. This suggests a possible upside of 7,146.4% from the stock's current price. View Analyst Price Targets for Auris Medical.

What is the consensus analysts' recommendation for Auris Medical?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Auris Medical in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Auris Medical.

Has Auris Medical been receiving favorable news coverage?

Media headlines about EARS stock have trended somewhat positive on Saturday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Auris Medical earned a news impact score of 0.7 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Auris Medical.

Are investors shorting Auris Medical?

Auris Medical saw a decline in short interest in November. As of November 15th, there was short interest totalling 39,800 shares, a decline of 38.0% from the October 31st total of 64,200 shares. Based on an average daily trading volume, of 133,500 shares, the short-interest ratio is presently 0.3 days. Currently, 2.5% of the company's stock are sold short. View Auris Medical's Current Options Chain.

Who are some of Auris Medical's key competitors?

What other stocks do shareholders of Auris Medical own?

Who are Auris Medical's key executives?

Auris Medical's management team includes the folowing people:
  • Dr. Thomas Meyer, Founder, Chairman, CEO & MD (Age 51)
  • Mr. Hernan Levett C.P.A., CPA, Chief Financial Officer (Age 43)
  • Colleen A. DeVries, SVP of Cogency Global Inc.

Who are Auris Medical's major shareholders?

Auris Medical's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Sabby Management LLC (8.96%).

Which institutional investors are buying Auris Medical stock?

EARS stock was bought by a variety of institutional investors in the last quarter, including Sabby Management LLC.

How do I buy shares of Auris Medical?

Shares of EARS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Auris Medical's stock price today?

One share of EARS stock can currently be purchased for approximately $1.38.

How big of a company is Auris Medical?

Auris Medical has a market capitalization of $2.59 million. The biotechnology company earns $-11,750,000.00 in net income (profit) each year or ($14.80) on an earnings per share basis. Auris Medical employs 9 workers across the globe.View Additional Information About Auris Medical.

What is Auris Medical's official website?

The official website for Auris Medical is http://www.aurismedical.com/.

How can I contact Auris Medical?

Auris Medical's mailing address is BAHNHOFSTRASSE 21, ZUG V8, 6300. The biotechnology company can be reached via phone at 41-41-729-7194 or via email at [email protected]

MarketBeat Community Rating for Auris Medical (NASDAQ EARS)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  353 (Vote Outperform)
Underperform Votes:  341 (Vote Underperform)
Total Votes:  694
MarketBeat's community ratings are surveys of what our community members think about Auris Medical and other stocks. Vote "Outperform" if you believe EARS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EARS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/7/2019 by MarketBeat.com Staff

Featured Article: Insider Trading

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel